{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:32:38Z","timestamp":1787311958816,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The long-term (around 1-year) effectiveness and safety of deucravacitinib for the treatment of psoriasis have not been extensively studied in real-world settings, particularly in difficult-to-treat areas, such as the genital, scalp and nail regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the 52-week real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe psoriasis of the genital, scalp and nail regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study analysed 104 patients with moderate-to-severe plaque psoriasis treated with deucravacitinib. Clinical scores, Psoriasis Area and Severity Index (PASI), both static and site-specific Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and laboratory inflammatory indices were assessed during a 52-week period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Deucravacitinib decreased clinical severity scores, and the decrease was sustained for 52 weeks. At week 52, 86% (37\/43), 63% (27\/43) and 26% (11\/43) of patients achieved PASI 75, PASI 90 and PASI 100 reductions (representing a \u2265 75%, \u2265 90% or 100% improvement from baseline), respectively. Deucravacitinib reduced the PGA scores for the genital, scalp and nail regions, as well as the DLQI. Among the patients who completed the 52-week treatment, no significant impact on laboratory inflammatory indices was observed, and no severe or lethal adverse events were reported. Not all patients completed the full 52-week treatment period, as some discontinued early due to adverse events or for other reasons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Deucravacitinib may be a promising long-term treatment option for psoriasis, demonstrating sustained effectiveness and safety, including in difficult-to-treat areas, such as the genital, scalp and nail regions in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llae530","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T23:24:28Z","timestamp":1733354668000},"page":"952-959","source":"Crossref","is-referenced-by-count":19,"title":["Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital , Inzai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic , Funabashi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital , Inzai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2025042411075595600_llae530-B1","doi-asserted-by":"crossref","first-page":"1286344","DOI":"10.3389\/fimmu.2023.1286344","article-title":"Crosstalk: keratinocytes and immune cells in psoriasis","volume":"14","author":"Kamata","year":"2023","journal-title":"Front Immunol"},{"key":"2025042411075595600_llae530-B2","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025042411075595600_llae530-B3","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"2025042411075595600_llae530-B4","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3390\/jcm12051934","article-title":"Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis","volume":"12","author":"Hagino","year":"2023","journal-title":"J Clin Med"},{"key":"2025042411075595600_llae530-B5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"key":"2025042411075595600_llae530-B6","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.jaci.2022.03.014","article-title":"TYK-ing all the boxes in psoriasis","volume":"149","author":"Schlapbach","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025042411075595600_llae530-B7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025042411075595600_llae530-B8","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025042411075595600_llae530-B9","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"2025042411075595600_llae530-B10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025042411075595600_llae530-B11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025042411075595600_llae530-B12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2023.11.060","article-title":"Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis","volume":"90","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025042411075595600_llae530-B13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1346-8138.16740","article-title":"Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial","volume":"50","author":"Imafuku","year":"2023","journal-title":"J Dermatol"},{"key":"2025042411075595600_llae530-B14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J Dermatol"},{"key":"2025042411075595600_llae530-B15","doi-asserted-by":"crossref","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","article-title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan","volume":"35","author":"Hagino","year":"2024","journal-title":"J Dermatol Treat"},{"key":"2025042411075595600_llae530-B16","doi-asserted-by":"crossref","first-page":"e12589","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola","year":"2018","journal-title":"Dermatol Ther"},{"key":"2025042411075595600_llae530-B17","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","article-title":"Genital psoriasis is associated with significant impairment in quality of life and sexual functioning","volume":"72","author":"Ryan","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025042411075595600_llae530-B18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/09546634.2018.1453125","article-title":"Prevalence of genital psoriasis in patients with psoriasis","volume":"29","author":"Meeuwis","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"2025042411075595600_llae530-B19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13555-017-0204-3","article-title":"Patients\u2019 perspectives on the impact of genital psoriasis: a qualitative study","volume":"7","author":"Cather","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025042411075595600_llae530-B20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ced\/llae312","article-title":"Effectiveness of deucravacitinib for genital, nail and scalp lesions with psoriasis: a 24-week real-world study","volume":"50","author":"Hagino","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2025042411075595600_llae530-B21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14740338.2024.2351462","article-title":"Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation","volume":"23","author":"Potestio","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2025042411075595600_llae530-B22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/15569527.2013.834498","article-title":"Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis","volume":"33","author":"Sen","year":"2014","journal-title":"Cutan Ocul Toxicol"},{"key":"2025042411075595600_llae530-B23","first-page":"e13457","article-title":"Neutrophil\/platelet to lymphocyte ratio in monitoring of response to TNF-\u03b1 inhibitors in psoriatic patients","volume":"33","author":"Nobari N","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025042411075595600_llae530-B24","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0230","article-title":"Predictive factors for long-term high responders to upadacitinib treatment in patients with atopic dermatitis","author":"Hagino","year":"2024","journal-title":"Dermatitis"},{"key":"2025042411075595600_llae530-B25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/1346-8138.17186","article-title":"Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: a single-center retrospective study","volume":"51","author":"Hagino","year":"2024","journal-title":"J Dermatol"},{"key":"2025042411075595600_llae530-B26","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.12257","article-title":"C-reactive protein in psoriasis: a review of the literature","volume":"28","author":"Beygi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411075595600_llae530-B27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1346-8138.13061","article-title":"Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis","volume":"43","author":"Kim","year":"2016","journal-title":"J Dermatol"},{"key":"2025042411075595600_llae530-B28","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.3390\/jcm12083046","article-title":"Impact of pretreatment systemic inflammatory markers on treatment persistence with biologics and conventional systemic therapy: a retrospective study of patients with psoriasis vulgaris and psoriatic arthritis","volume":"12","author":"Sugimoto","year":"2023","journal-title":"J Clin Med"},{"key":"2025042411075595600_llae530-B29","doi-asserted-by":"crossref","first-page":"1323174","DOI":"10.3389\/fimmu.2024.1323174","article-title":"Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: evidence from NHANES","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"2025042411075595600_llae530-B30","doi-asserted-by":"crossref","first-page":"5701949","DOI":"10.1155\/2020\/5701949","article-title":"Low systemic inflammation response index predicts good prognosis in locally advanced pancreatic carcinoma patients treated with concurrent chemoradiotherapy","volume":"2020","author":"Topkan","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"2025042411075595600_llae530-B31","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.3390\/ijms23179553","article-title":"Investigation of the associations of novel inflammatory biomarkers \u2013 \u200csystemic inflammatory index (SII) and systemic inflammatory response index (SIRI)\u00a0\u2013 \u200cwith the severity of coronary artery disease and acute coronary syndrome occurrence","volume":"23","author":"Dziedzic","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025042411075595600_llae530-B32","doi-asserted-by":"crossref","first-page":"e13230","DOI":"10.1111\/eci.13230","article-title":"Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease","volume":"50","author":"Yang","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"2025042411075595600_llae530-B33","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.032","article-title":"Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: a 24-week real-world study","author":"Hagino","year":"2024","journal-title":"Dermatitis"},{"key":"2025042411075595600_llae530-B34","first-page":"793","article-title":"The Static Physician's Global Assessment of Genitalia: a clinical outcome measure for the severity of genital psoriasis","volume":"16","author":"Merola","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"2025042411075595600_llae530-B35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bjd.17689","article-title":"Localization of treatment-resistant areas in patients with psoriasis on biologics","volume":"181","author":"Hjuler","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025042411075595600_llae530-B36","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3353","article-title":"Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial","volume":"100","author":"Guenther","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025042411075595600_llae530-B37","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1111\/jdv.19562","article-title":"Risankizumab for the treatment of genital psoriasis: a 1-year, real-world experience","volume":"38","author":"Orsini","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411075595600_llae530-B38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14712598.2023.2236023","article-title":"Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study","volume":"23","author":"Mastorino","year":"2023","journal-title":"Expert Opin Biol Ther"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae530\/60972603\/llae530.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/952\/60972603\/llae530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/952\/60972603\/llae530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:08:09Z","timestamp":1745492889000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/5\/952\/7918389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae530","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,6]]}}}